<div id="readability-page-1"><p>Royce &amp; Associates LP acquired a new position in  Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor  acquired 510,000 shares of the medical device company's stock, valued at approximately $6,191,000. Royce &amp; Associates LP owned approximately 0.75% of Tandem Diabetes Care at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Tandem Diabetes Care</strong> alerts:</span></p></div><p>Other institutional investors and hedge funds have also recently modified their holdings of the company. Amalgamated Bank boosted its holdings in  Tandem Diabetes Care by 3.5% in the 3rd quarter. Amalgamated Bank now owns 19,617 shares of the medical device company's stock worth $238,000 after buying an additional 657 shares during the period.  Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in  Tandem Diabetes Care by 8.8% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,101 shares of the medical device company's stock valued at $319,000 after buying an additional 1,384 shares during the last quarter.  Police &amp; Firemen s Retirement System of New Jersey grew its holdings in  Tandem Diabetes Care by 10.1% during the 2nd quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 15,299 shares of the medical device company's stock valued at $285,000 after buying an additional 1,399 shares in the last quarter.  PNC Financial Services Group Inc. increased its stake in  Tandem Diabetes Care by 8.9% in the 2nd quarter. PNC Financial Services Group Inc. now owns 20,954 shares of the medical device company's stock worth $391,000 after acquiring an additional 1,719 shares during the last quarter.  Finally, Diversified Trust Co increased its stake in  Tandem Diabetes Care by 12.2% in the 3rd quarter. Diversified Trust Co now owns 18,339 shares of the medical device company's stock worth $223,000 after acquiring an additional 1,991 shares during the last quarter. </p><h2>Tandem Diabetes Care Trading Down 1.4%</h2><p>TNDM opened at $23.41 on Thursday. The company has a quick ratio of 2.02, a current ratio of 2.55 and a debt-to-equity ratio of 2.00. The stock's fifty day moving average is $21.42 and its two-hundred day moving average is $17.82. The company has a market capitalization of $1.60 billion, a P/E ratio of -7.63 and a beta of 1.63. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $29.65. </p><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Thursday, February 19th. The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04. The firm had revenue of $290.38 million during the quarter, compared to analysts' expectations of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The company's revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.01 EPS.  Analysts forecast that  Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year. </p><h2>Analysts Set New Price Targets</h2><p>TNDM has been the subject of a number of research reports. Barclays  reiterated an &#34;overweight&#34; rating and set a $56.00 target price on shares of Tandem Diabetes Care in a research report on Monday, February 23rd. Sanford C. Bernstein  reiterated a &#34;market perform&#34; rating and set a $25.00 price objective (up from $18.00) on shares of Tandem Diabetes Care in a research report on Friday, January 9th. Mizuho  set a $22.00 price objective on shares of Tandem Diabetes Care and gave the stock a &#34;neutral&#34; rating in a research note on Friday, February 20th. Lake Street Capital upgraded shares of Tandem Diabetes Care from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $50.00 target price on the stock in a research report on Monday, February 23rd. Finally, UBS Group  reaffirmed a &#34;neutral&#34; rating and issued a $22.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, February 20th. One investment analyst  has rated the stock with a Strong Buy rating, six have assigned  a Buy rating, eleven have assigned  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock  has a consensus rating of &#34;Hold&#34; and a consensus price target of $28.11.</p><p><b>Get Our Latest Stock Report on Tandem Diabetes Care</b></p><h2>Tandem Diabetes Care Profile</h2> (Free Report)<p>Tandem Diabetes Care, Inc <span>NASDAQ: TNDM<span></span></span>, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.  </p><p>The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.</p><h2>Read More</h2><ul><li>Five stocks we like better than Tandem Diabetes Care</li><li>The gold chart Wall Street is terrified of…</li><li>America’s 1776 happening again</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

TNDM

<p>Royce & Associates LP has acquired a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM), purchasing 510,000 shares valued at approximately $6.19 million. This investment represents about 0.75% of the company. Other institutional investors have also increased their stakes in Tandem. The stock opened at $23.41, with a market cap of $1.60 billion and a P/E ratio of -7.63. Analysts have set various price targets, with a consensus rating of "Hold" and a target price of $28.11.</p>

Market Beat

ALPS Medical Breakthrough

SPDR S&P Health Equip

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares US Medical Devices

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Tandem Diabetes

Royce & Associates LP Makes New Investment in Tandem Diabetes Care, Inc. $TNDM